In this week’s video, Dr. Brian G.M. Durie discusses daratumumab’s presence and results in the frontline setting.

BOTTOM LINE: 
​Daratumumab has been successful in the frontline setting for myeloma patients. It will prove to be a new standard of care in many combinations to come.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org

Previous Post
ODAC Votes Against Accelerated Approval for Selinexor
Next Post
Is there a link between MGUS and kidney damage in myeloma patients?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.